Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid

doi:10.1016/0304-3940(84)90050-8

Neuroscience Letters

Volume 48, Issue 3, 10 August 1984, Pages 273-278

https://doi.org/10.1016/0304-3940(84)90050-8 Get rights and content

Abstract

Kynurenic acid (KYNA) was tested as an antagonist of the neurotoxic and epileptogenic effects of the metabolically related brain constituent quinolinic acid (QUIN). In the rat striatum, KYNA blocked the neurotoxic effects of QUIN in preference to those of other excitotoxins. In the hippocampus, KYNA antagonized both the neurodegeneration and seizures caused by the local application of QUIN. These properties of KYNA raise the possibility of a functional link between KYNA and QUIN in the brain which may be of relevance for an understanding of human neurodegenerative disorders.

References (21)

A.C. Foster et al.
On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds
Neuropharmacology
(1983)
A.H. Ganong et al.
Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord
Brain Res.
(1983)
L.M. Henderson et al.
Quinolinic acid metabolism. I. Urinary excretion by the rat following tryptophan and 3-hydroxy-anthranilic acid administration
J. biol. Chem.
(1949)
M. Joseph
The determination of kynurenine; a simple gas-liquid chromatographic method applicable to urine, plasma, brain and CSF
J. Chromat.
(1978)
C. Köhler et al.
Comparison of ibotenate and kainate neurotoxicity in rat brain: a histological study
Neuroscience
(1983)
H. McLennan et al.
The antagonism of amino acid-induced excitation of spinal neurons in the cat
Brain Res.
(1979)
M.N. Perkins et al.
An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid
Brain Res.
(1982)
M.N. Perkins et al.
Quinolinic acid: regional variations in neuronal sensitivity
Brain Res.
(1983)
R. Schwarcz et al.
Seizure activity and lesions after intrahippocampal quinolinic acid injection
Exp. Neurol.
(1984)
R. Schwarcz et al.
α-Amino-ω-phosphono carboxylates block ibotenate but not kainate neurotoxicity in rat hippocampus
Neurosci. Lett.
(1982)

There are more references available in the full text version of this article.

Cited by (375)

Metabolomics on depression: A comparison of clinical and animal research
2024, Journal of Affective Disorders
Depression is a major cause of suicide and mortality worldwide. This study aims to conduct a systematic review to identify metabolic biomarkers and pathways for major depressive disorder (MDD), a prevalent subtype of clinical depression.
We searched for metabolomics studies on depression published between January 2000 and January 2023 in the PubMed and Web of Science databases. The reported metabolic biomarkers were systematically evaluated and compared. Pathway analysis was implemented using MetaboAnalyst 5.0.
We included 26 clinical studies on MDD and 78 metabolomics studies on depressive-like animal models. A total of 55 and 77 high-frequency metabolites were reported consistently in two-thirds of clinical and murine studies, respectively. In the comparison between murine and clinical studies, we identified 9 consistently changed metabolites (tryptophan, tyrosine, phenylalanine, methionine, fumarate, valine, deoxycholic acid, pyruvate, kynurenic acid) in the blood, 1 consistently altered metabolite (indoxyl sulfate) in the urine and 14 disturbed metabolic pathways in both types of studies. These metabolic dysregulations and pathways are mainly implicated in enhanced inflammation, impaired neuroprotection, reduced energy metabolism, increased oxidative stress damage and disturbed apoptosis, laying solid molecular foundations for MDD.
Due to unavailability of original data like effect-size results in many metabolomics studies, a meta-analysis cannot be conducted, and confounding factors cannot be fully ruled out.
This systematic review delineated metabolic biomarkers and pathways related to depression in the murine and clinical samples, providing opportunities for early diagnosis of MDD and the development of novel diagnostic targets.
Effects of different chronic restraint stress periods on anxiety- and depression-like behaviors and tryptophan-kynurenine metabolism along the brain-gut axis in C57BL/6N mice
2024, European Journal of Pharmacology
Chronic restraint stress (CRS) is a widely used stimulus to induce anxiety- and depression-like behaviors, linked to alterations in tryptophan-kynurenine (TRP-KYN) metabolism in animals. This study assessed the effects of different CRS periods on anxiety- or depression-like behaviors and TRP-KYN metabolism along brain-gut axis in C57BL/6N mice. Results showed that one-week CRS decreased the open arm entries of mice in elevated plus maze and delayed latency of feeding in novelty suppressed feeding test. Four-week CRS reduced sucrose preference, increases forced swimming immobility time, and also induced anxiety-like behaviors of mice. UPLC-MS/MS analysis revealed decreased levels of the neurotoxic 3-hydroxykynurenine (3-HK) and quinolinic acid (QA), and an increase in the neuroprotective kynurenic acid (KA) in the hippocampus of one-week CRS mice; meanwhile, four-week CRS mice displayed a reduction in KA and increases in 3-HK and QA. In the colon, both one-week and four-week CRS mice exhibited significant reductions in 3-HK and QA, with a marked increase of KA exclusively in four-week CRS mice. Briefly, one-week CRS only induced anxiety-like behaviors with hippocampal neuroprotection in TRP-KYN metabolism, whereas four-week CRS caused anxiety- and depression-like behaviors with neurotoxicity. In the colon, during both CRS periods, KYN was metabolized in the direction of NAD⁺ production. However, four-week CRS triggered intestinal inflammation risk with increased KA. Summarily, slightly short-term stress has beneficial effects on mice, while prolonged chronic stress can lead to pathological changes. This study offers valuable insights into stress-induced emotional disturbances.
The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis
2023, Journal of Affective Disorders
A disruption of the kynurenine (KYN) pathway may exist in major depressive disorder (MDD). However, the changing pattern of the KYN pathway across the different disease states in MDD is unclear. Herein, we performed a meta-analysis to examine the differences in KYN metabolites between patients in the current episode of MDD (cMDD) and patients in remission (rMDD), as well as the changes after treatments.
Literature was systematically searched from electronic databases, from inception up to September 2022. Random-effect models were used to quantify the differences in KYN metabolites between patients with MDD across acute depressive episode and remission phases, as well as the changes after treatments.
Fifty-one studies involving 7056 participants were included. Tryptophan (TRP), KYN, kynurenic acid (KYNA), KYNA/quinolinic acid (QA), KYNA/3-hydroxykynurenine (3-HK), and KYNA/KYN were significantly lower, while KYN/TRP was significantly higher in patients with cMDD. Moreover, these effect sizes were generally larger in medication-free patients. No significant differences were found between patients with rMDD and HCs. Additionally, KYNA was found negatively correlated with depression severity and significantly increased after treatments, while the alteration was not found in QA.
The number of included studies of patients with rMDD and longitudinal studies investigating the change of the KYN metabolites after treatment with antidepressants was limited. In addition, the heterogeneity across included studies was relatively high.
These findings showed a comprehensive image of the unique dysfunction pattern of the KYN pathway across different MDD states and highlighted KYNA as a potentially sensitive biomarker of MDD.
Relationship of tryptophan metabolites with the type and severity of multiple sclerosis
2023, Multiple Sclerosis and Related Disorders
Tryptophan is an essential amino acid primarily metabolized by the kynurenine pathway in mammals. Intermediate metabolites emerging in this pathway have been associated with many neurogenerative diseases. This study aimed to compare tryptophan pathway metabolite levels in patients with multiple sclerosis (MS) and healthy controls and reveal the relationship of tryptophan metabolites with disease subtype and the Expanded Disability Status Scale (EDSS) score.
The study included a total of 80 MS cases [53 with relapsing remitting MS (RRMS) and 27 with secondary progressive MS (SPMS)] and 41 healthy volunteers. The patients with RRMS were further divided into relapse (RRMS-attack) and non-attack (RRMS-stable) groups. Using liquid chromatography mass spectrometry, tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid levels were measured. The serum metabolite levels of the patient and control groups were compared. In addition, the link and relationship between the EDSS score and disease duration of the patients and their plasma tryptophan metabolite levels were examined.
The tryptophan level of the patient group was significantly lower than that of the healthy controls (p<0.05). The kynurenine (105.38±65.43), quinolinic acid (10.42±3.56), kynurenine/tryptophan ratio (0.0218±0.019), and quinolinic acid/kynurenic acid ratio (1.7054±0.96141) of the patients with MS were significantly higher compared to the controls (p<0.05). In the receiver operating characteristic analysis of the power of kynurenine/tryptophan and quinolinic acid/kynurenic acid ratios in predicting the disease, both ratios predicted the diagnosis of MS (area under the curve: 0.793 and 0.645, respectively; p<0.05), albeit at low sensitivity and specificity. The parameters were similar between the RRMS-attack and RRMS-stable patient groups (p>0.05). There was also no significant difference between the RRMS and SPMS patient groups in terms of tryptophan metabolites (p>0.05). Lastly, no significant relationship was observed between tryptophan metabolites and MS subtype and the EDSS score.
Our findings revealed that the kynurenine pathway involved in the tryptophan metabolism differed between the patients with MS and healthy controls, and this difference may be a limited guide in the diagnosis of MS, due to major overlaps in values for MS versus Controls, and is insufficient to determine the disease subtype.
Tryptophan-kynurenine metabolic characterization in the gut and brain of depressive-like rats induced by chronic restraint stress
2023, Journal of Affective Disorders
Accumulating evidence revealed the role of tryptophan (TRP) metabolism, especially its kynurenine pathway (KP), in the communication along the gut-brain axis. However, the underlying characterization of such interaction was not precise. In the present study, the rat depression model was induced by chronic restraint stress (CRS). After depression behavior tests, seven segments (cortex, hippocampus, striatum, hypothalamus, serum, cecum, and colon) along the gut-brain axis were collected to characterize their KP metabolism. mRNA expression of IL-1β, IFN-γ, IL-10 and indoleamine 2,3-dioxygenase 1 (IDO1) enzyme revealed a general inflammatory response and region-specific activated IDO1 along the gut-brain axis. Determination of KP metabolites and enzymes displayed a general KP activation with region-specificity, especially in the hippocampus and colon, where the changes were more pronounced. KYN and 3-HK were increased dramatically along the gut-brain axis; hippocampal KA revealed a significant decrease while colonic KA showed a notable increase, evidenced by the same alternation trends of the corresponding enzymes. The expression of quinolinic acid phosphoribosyltransferase (QPRT), the crucial enzyme to produce NAD⁺ from QA, was significantly upregulated in the gut but not changed in the brain. Pearson's correlation analysis suggested that kynurenine (KYN), 3-hydroxycaninuric acid (3-HK), serotonin (5-HT), TRP and kynurenic acid (KA) significantly correlated with depressive behaviors in rats. Furthermore, western blot analysis on nod-like receptor protein 3/2 (NLRP3/NLRP2) inflammasome signaling displayed that NLRP3 and cleaved IL-1β/caspase-1 were significantly activated in the hippocampus and colon of CRS rats. However, NLRP2 was only activated in the hippocampus. These results revealed CRS induced inflammatory responses along the brain-gut axis of rats might be controlled through the NLRP3/NLRP2 inflammasome signaling pathway, which may be the underlying regulator for CRS-induced TRP-KYN metabolic changes. This study provides a new experimental background for developing stress-related health products.
The effect of electroconvulsive therapy (ECT) on serum kynurenine pathway metabolites in late-life depression
2023, Journal of Affective Disorders Reports
Depression is reportedly associated with alterations in kynurenine pathway metabolites (kynurenines). Several kynurenines are involved in glutamate signaling, and some have potentially neurotoxic effects while others are considered neuroprotective. The pathway is upregulated under inflammatory conditions, which is associated with depression. Modulation of kynurenine metabolism has been investigated as a potential mechanism in electroconvulsive therapy (ECT), an effective treatment for major depressive disorder, particularly in late-life depression. However, results have been inconclusive. Here we aimed to investigate changes in tryptophan and kynurenines in older patients treated with ECT.
We analyzed levels of tryptophan, eight kynurenine pathway metabolites and the inflammation marker neopterin in serum samples collected at baseline and after a full ECT series for 48 patients with late-life depression from the Dutch MODECT study.
There were no significant changes in the concentration of single metabolites after ECT, but a significant reduction in the ratio of kynurenic acid to 3-hydroxykynurenine (KA/HK). Analyses of change in kynurenines after ECT in remitters and non-remitters revealed no clear patterns or link to the therapeutic effect of ECT. There was considerable covariation between neopterin and several kynurenines.
Variations in diet and serum collection timing may have impacted the results.
This study did not show consistent changes in the kynurenine pathway activation or balance between neuroactive metabolites after ECT. Still, changes in kynurenines were strongly related to changes in neopterin concentrations. This demonstrates the importance of considering inflammation when investigating the effect of ECT on the kynurenine pathway.

View all citing articles on Scopus

^∗: Permanent address: Istituto Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy.

View full text

Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid

Abstract

Neuropharmacology

Brain Res.

J. biol. Chem.

J. Chromat.

Neuroscience

Brain Res.

Brain Res.

Brain Res.

Exp. Neurol.

Neurosci. Lett.